EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer
Arend, Rebecca C., Davis, Allison M., Chimiczewski, Przemyslaw, O'Malley, David M., Provencher, Diane, Vergote, Ignace, Ghamande, Sharad, Birrer, Michael J.Journal:
Gynecologic Oncology
DOI:
10.1016/j.ygyno.2019.12.002
Date:
December, 2019
File:
PDF, 870 KB
2019
File converter
More search results
More benefits 
